XSPRAY Xspray Pharma AB (publ)
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Xspray Pharma (STO: XSPRAY)
›
Xspray Pharma (STO: XSPRAY) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 24 employees.
The shares were at 10.18 SEK on 20 November 2026, down 61.1% over 52 weeks. Its 52-week range is 9.060 SEK to 36.15 SEK: the price is 71.8% below the high and 12.4% above the low.
Its market capitalisation is 506.55M SEK.
Xspray Pharma reports return on equity of -28.4% and revenue down 41.1% year over year.
Its debt exceeds its cash by 7.50M SEK, a debt-to-equity ratio of 0.25. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 37.20 SEK is 265.4% above the current price.